EMAIL THIS PAGE TO A FRIEND

Oncotarget

Mitochondrial morphology is altered in atrophied skeletal muscle of aged mice.


PMID 26053100

Abstract

Skeletal muscle aging is associated with a progressive decline in muscle mass and strength, a process termed sarcopenia. Evidence suggests that accumulation of mitochondrial dysfunction plays a causal role in sarcopenia, which could be triggered by impaired mitophagy. Mitochondrial function, mitophagy and mitochondrial morphology are interconnected aspects of mitochondrial biology, and may coordinately be altered with aging. However, mitochondrial morphology has remained challenging to characterize in muscle, and whether sarcopenia is associated with abnormal mitochondrial morphology remains unknown. Therefore, we assessed the morphology of SubSarcolemmal (SS) and InterMyoFibrillar (IMF) mitochondria in skeletal muscle of young (8-12wk-old) and old (88-96wk-old) mice using a quantitative 2-dimensional transmission electron microscopy approach. We show that sarcopenia is associated with larger and less circular SS mitochondria. Likewise, aged IMF mitochondria were longer and more branched, suggesting increased fusion and/or decreased fission. Accordingly, although no difference in the content of proteins regulating mitochondrial dynamics (Mfn1, Mfn2, Opa1 and Drp1) was observed, a mitochondrial fusion index (Mfn2-to-Drp1 ratio) was significantly increased in aged muscles. Our results reveal that sarcopenia is associated with complex changes in mitochondrial morphology that could interfere with mitochondrial function and mitophagy, and thus contribute to aging-related accumulation of mitochondrial dysfunction and sarcopenia.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M6319
Anti-Mitofusin-2 (N-Terminal) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
T1378
Sigma 7-9®, ≥99% (titration), crystalline
C4H11NO3
154563
Tris(hydroxymethyl)aminomethane, ultrapure grade, ≥99.9%
C4H11NO3
252859
Tris(hydroxymethyl)aminomethane, ACS reagent, ≥99.8%
C4H11NO3
RDD008
Trizma® base, anhydrous, free-flowing, Redi-Dri, ≥99.9%
C4H11NO3
T1503
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline
C4H11NO3
T6066
Trizma® base, BioPerformance Certified, meets EP, USP testing specifications, cell culture tested, ≥99.9% (titration)
C4H11NO3
T6791
Trizma® base, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
C4H11NO3
T4661
Trizma® base, ≥99.9% (titration), crystalline
C4H11NO3
93362
Trizma® base, BioUltra, for molecular biology, ≥99.8% (T)
C4H11NO3
93352
Trizma® base, ≥99.0% (T)
C4H11NO3
93350
Trizma® base, puriss. p.a., ≥99.7% (T)
C4H11NO3
33742
Trizma® base, puriss. p.a., buffer substance, ≥99.5%
C4H11NO3
T6687
Tromethamine, meets USP testing specifications
C4H11NO3
RES3137T-A7
Tromethamine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production., suitable for cell culture, meets USP testing specifications
C4H11NO3
RES3193T-A7
Tromethamine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture, Meets USP, EP, JPC, BP testing specifications.
C4H11NO3